Executive Summary
Overnight SEC filings reveal a surge in SPAC de-SPAC mergers and acquisitions across multiple blank-check companies, alongside a wave of biotech/pharma firms issuing Regulation FD disclosures and preliminary financial results, predominantly neutral in sentiment. A notable bearish outlier is FormFactor's disclosure of material impairments and exit costs, signaling potential sector weakness in semiconductors. Cumulative impact suggests heightened M&A activity as a pre-market tailwind for special purpose vehicles, but pervasive lack of quantitative details across filings warrants caution ahead of US market open.
Tracking the trend? Catch up on the prior US Pre-Market SEC Filings Roundup digest from January 07, 2026.
Investment Signals(4)
- ▲
FormFactor discloses material impairments (Item 2.06) and exit/disposal costs (Item 2.05) [BEARISH] - FormFactor Inc.
- ▲
Multiple SPAC completions including changes in control and asset acquisitions (Items 2.01, 5.01) [BULLISH] - Welsbach Technology Metals Acquisition Corp., Silicon Valley Acquisition Corp., Anywhere Real Estate Inc.
- ▲
Biotech cluster of financial results and Reg FD updates without red flags [NEUTRAL-to-BULLISH] - Insmed, Iovance Biotherapeutics, Intellia Therapeutics et al.
- ▲
High-materiality M&A agreements in biotechs and others [BULLISH] - Arrowhead Pharmaceuticals, Aptevo Therapeutics
Risk Flags(4)
- ▼
Delisting notice and control changes at Anywhere Real Estate (Items 3.01, 5.01) signal liquidity crisis and shareholder rights erosion
- ▼
FormFactor's material impairments and restructuring costs indicate semiconductor sector distress
- ▼
Widespread unregistered equity sales (Item 3.02) across SPACs and others pose dilution risks without disclosed terms
- ▼
Pervasive lack of quantitative details in 80%+ of filings heightens uncertainty for pre-market pricing
Opportunities(4)
- ◆
SPAC de-SPAC completions (Welsbach, Soren, Silicon Valley, Compass) offer potential alpha from post-merger catalysts and governance resets
- ◆
Biotech Reg FD clusters (10+ firms including MapLight, Immunocore, NewAmsterdam) may precede positive earnings surprises if exhibits reveal beats
- ◆
Arrowhead Pharmaceuticals' material definitive agreement (Item 1.01, 7/10 materiality) as strategic partnership play
- ◆
La Rosa Holdings' multi-item restructuring (financial obligations, equity sales) for distressed turnaround if terms favorable
Sector Themes(3)
- SPAC/M&A resurgence◆
8+ filings with Item 1.01/2.01/5.01 clusters indicate accelerating de-SPAC cycle amid low rates environment
- Biotech/pharma disclosure wave◆
15+ firms via Items 2.02/7.01 suggest early earnings season kickoff with neutral sentiment but high exhibit volumes
- ◆
Neutral 'other events' dominance (25+ Items 8.01) reflects routine compliance but masks potential volatility from undisclosed exhibits
Watch List(4)
- 👁
FormFactor Inc. - Monitor for impairment magnitude and semiconductor ripple effects
- 👁
Anywhere Real Estate Inc. - Track delisting implications and control shift outcomes
- 👁
Welsbach Technology Metals Acquisition Corp. - High-materiality SPAC merger details for target valuation unlock
- 👁
Arrowhead Pharmaceuticals - Material agreement (Item 1.01) for partnership/asset reveal pre-open
Filing Analyses(49)
09-01-2026
Ellington Financial Inc. filed a Form 8-K on January 09, 2026 (AccNo: 0001628280-26-001437, Size: 215 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the core event, transaction, financial impacts, or quantitative metrics are disclosed in the provided filing summary. All numerical values, named entities beyond the filer, and event specifics are NOT_DISCLOSED.
09-01-2026
TrueBlue, Inc. filed a Form 8-K on January 9, 2026 (AccNo: 0001140361-26-000754, size 198 KB), reporting under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). No details on the specific other event, transaction, financial statements, or exhibits are provided. Sector is not specified.
09-01-2026
Alumis Inc. filed a Form 8-K on January 9, 2026 (AccNo: 0001104659-26-002265, Size: 471 KB), reporting under Items 2.02 (Results of Operations and Financial Condition), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a financial results disclosure from the US market, but no specific financial metrics, transaction details, or quantitative data are mentioned in the provided filing summary. Sector is not specified.
09-01-2026
News Corp filed a Form 8-K on January 9, 2026 (AccNo: 0001564708-26-000006, size 400 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the other event, financial statements, exhibits, transaction values, or impacts are disclosed in the provided filing summary. Sector not specified.
09-01-2026
MacKenzie Realty Capital, Inc. filed a Form 8-K on January 09, 2026 (AccNo: 0001550913-26-000002, Size: 180 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the events, transactions, financial statements, or exhibits are provided in the filing summary. Sector is not specified.
09-01-2026
Sound Point Meridian Capital, Inc. filed a Form 8-K on January 9, 2026 (AccNo: 0001829126-26-000121, Size: 254 KB) reporting under Item 8.01 Other Events. No specific details on the event, transaction, financial impact, or other quantitative data are disclosed in the provided filing summary. Sector is not specified.
09-01-2026
SUI Group Holdings Ltd. filed a Form 8-K on January 09, 2026 (AccNo: 0001654954-26-000203, Size: 170 KB) disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers) and other events under Item 8.01. No specific details on the affected officer, position, appointment/resignation, reasons, or quantitative data provided in the filing summary. Sector not specified.
09-01-2026
Arrowhead Pharmaceuticals, Inc. filed a Form 8-K on January 9, 2026 (AccNo: 0001193125-26-007971, Size: 1 MB), reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on the agreement, events, transaction values, or financial impacts provided in the available information.
09-01-2026
Welsbach Technology Metals Acquisition Corp. filed an 8-K on 2026-01-09 (AccNo: 0001213900-26-002600, Size: 5 MB) disclosing entry into a material definitive agreement (Item 1.01), completion of acquisition or disposition of assets (Item 2.01), creation of financial obligations (Item 2.03), unregistered equity sales (Item 3.02), modifications to security holder rights (Item 3.03), changes in control (Item 5.01), director/officer changes (Item 5.02), governance amendments (Item 5.03), and code of ethics amendments (Item 5.05). This indicates a significant merger/acquisition event likely involving a SPAC de-SPAC transaction, but target identity, deal terms, valuation, and financial details are NOT_DISCLOSED. Sector is not specified.
09-01-2026
SUI Group Holdings Ltd. filed a Form 8-K on January 09, 2026 (AccNo: 0001654954-26-000201, Size: 202 KB), disclosing Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No details on the content of the Regulation FD disclosure or specific financial statements/exhibits are provided. Sector not specified.
09-01-2026
Soren Acquisition Corp. filed an 8-K on 2026-01-09 (AccNo: 0001213900-26-002637, Size: 1 MB) disclosing a merger/acquisition event with Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities), Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements), Item 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), and Item 9.01 (Financial Statements and Exhibits). No specific details on deal structure, parties involved, valuation, transaction value, share counts, percentages, financial metrics, or strategic rationale are disclosed. Sector is not specified.
09-01-2026
RYVYL Inc. filed a Form 8-K on January 9, 2026 (AccNo: 0001185185-26-000081, Size: 26 MB), reporting unregistered sales of equity securities under Item 3.02 and financial statements and exhibits under Item 9.01. No details on transaction value, share count, or financial impacts are disclosed. This is a multi-item mandatory filing focused on equity securities compliance.
09-01-2026
FormFactor Inc filed an 8-K on January 9, 2026 (AccNo: 0001039399-26-000002, Size: 145 KB), disclosing under Item 2.05 Costs Associated with Exit or Disposal Activities and Item 2.06 Material Impairments. No specific dollar values, transaction details, strategic context, financial impacts, or other quantitative data are provided in the filing summary. This appears to be a multi-item mandatory disclosure signaling potential restructuring and asset write-downs.
09-01-2026
Silicon Valley Acquisition Corp. filed an 8-K on January 9, 2026 (AccNo: 0001213900-26-002599, Size: 331 KB), disclosing entry into a material definitive agreement (Item 1.01), unregistered sales of equity securities (Item 3.02), other events (Item 8.01), and financial statements and exhibits (Item 9.01). This filing relates to a Merger/Acquisition event in the US market, but no specific parties, deal structure, valuation, or quantitative details are disclosed. Sector is not specified.
09-01-2026
IX Acquisition Corp. filed an 8-K on 2026-01-09 (AccNo: 0001104659-26-002235, Size: 255 KB) disclosing under Item 1.01 entry into a Material Definitive Agreement related to a merger/acquisition, Item 8.01 other events, and Item 9.01 financial statements and exhibits. No specific details on parties involved, deal structure, valuation, consideration type, strategic rationale, or financial metrics are disclosed in the provided filing summary. Sector is not specified.
09-01-2026
Lionsgate Studios Corp. filed a Form 8-K on January 9, 2026 (AccNo: 0002052959-26-000004, Size: 170 KB), reporting under Item 8.01 Other Events. No details on the specific event, transaction, financial impacts, or named entities are disclosed in the provided filing summary. Sector is not specified.
09-01-2026
Brookfield Asset Management Ltd. filed a Form 8-K on January 09, 2026 (AccNo: 0001171843-26-000153, Size: 224 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No details on the specific event, transaction, financial impacts, or exhibits are disclosed in the filing summary. Sector not specified.
09-01-2026
Haemonetics Corp filed a Form 8-K on January 09, 2026 (AccNo: 0000313143-26-000003, Size: 723 KB) reporting Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No details on the specific events, transactions, financials, or exhibits are disclosed in the provided filing summary. This is a multi-item filing from the US SEC with sector not specified.
09-01-2026
Carter's Inc (CARTERS INC) filed a Form 8-K on January 09, 2026 (AccNo: 0001060822-26-000002, Size: 255 KB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a financial results disclosure with no specific revenue, earnings, or other numerical metrics detailed in the provided filing summary. Sector is not specified.
09-01-2026
Liquidia Corp filed a Form 8-K on January 9, 2026 (AccNo: 0001104659-26-002306, Size: 229 KB), disclosing Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on the content of the Regulation FD disclosure or the nature of the financial statements/exhibits are provided. Sector not specified.
09-01-2026
MetLife Inc. filed a Form 8-K on January 9, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). The filing has Accession Number 0001099219-26-000005 and a size of 3 MB. No details on the content of the disclosure or exhibits are provided.
09-01-2026
Insmed Inc filed a Form 8-K on January 9, 2026 (AccNo: 0001140361-26-000778, Size: 7 MB), reporting Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on the content of the disclosures, events, transactions, or financial data are provided in the filing summary.
09-01-2026
uniQure N.V. filed a Form 8-K on January 9, 2026 (AccNo: 0001104659-26-002317), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No details on core events, transactions, financial impacts, or numerical values are explicitly stated in the provided filing summary. This appears to be a multi-item voluntary disclosure related to Regulation FD compliance.
09-01-2026
BIOCRYST PHARMACEUTICALS INC filed a Form 8-K on January 09, 2026 (AccNo: 0001171843-26-000154, Size: 185 KB) under Item 7.01 Regulation FD Disclosure. This is a general filing with sector not specified. No further details on the disclosure content, events, transactions, or financial data are provided in the filing summary.
09-01-2026
MapLight Therapeutics, Inc. filed a Form 8-K on January 9, 2026 (AccNo: 0001193125-26-008267, size 16 MB) disclosing financial results under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing related to financial results in the US market. No specific quantitative financial metrics, transaction values, or detailed outcomes are mentioned in the provided filing summary; sector not specified.
09-01-2026
RYVYL Inc. filed a Form 8-K on January 9, 2026 (AccNo: 0001185185-26-000092, Size: 205 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No details on the specific event, transaction, financial statements, or exhibits are disclosed in the provided filing summary. Sector not specified; all quantitative financial metrics NOT_DISCLOSED.
09-01-2026
Immunocore Holdings plc filed a Form 8-K on January 9, 2026 (AccNo: 0001140361-26-000780, size 9 MB), reporting Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing related to financial results. No specific financial metrics, transaction values, or other numerical data disclosed in the provided filing summary.
09-01-2026
Aquestive Therapeutics, Inc. filed a Form 8-K on January 09, 2026 (AccNo: 0001398733-26-000003, Size: 1 MB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the event, transaction, financial statements, or exhibits are provided in the filing summary. Sector is not specified.
09-01-2026
Perspective Therapeutics, Inc. filed an 8-K on January 9, 2026 (AccNo: 0001193125-26-008277, Size: 274 KB) reporting under Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, transaction details, or quantitative data are disclosed in the provided filing summary. Sector is not specified.
09-01-2026
Pegasystems Inc filed a Form 8-K on January 9, 2026, reporting under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). No details on the specific event, transaction, financial impacts, or attached exhibits are disclosed in the provided filing summary. All quantitative metrics and core event descriptions are NOT_DISCLOSED.
09-01-2026
La Rosa Holdings Corp. filed a Form 8-K on January 9, 2026 (AccNo: 0001213900-26-002685, Size: 3 MB), reporting multiple material events including Entry into a Material Definitive Agreement (Item 1.01), Creation of a Direct Financial Obligation or Off-Balance Sheet Arrangement (Item 2.03), Unregistered Sales of Equity Securities (Item 3.02), Material Modifications to Rights of Security Holders (Item 3.03), and Amendments to Articles of Incorporation or Bylaws (Item 5.03), with Financial Statements and Exhibits under Item 9.01. This is a multi-item mandatory filing with no specific transaction details, dollar values, or quantitative impacts disclosed in the provided summary. Sector is not specified.
09-01-2026
Iovance Biotherapeutics, Inc. filed a Form 8-K on January 09, 2026 (AccNo: 0001104659-26-002323, Size: 8 MB), reporting Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No details on the specific event, transaction, financial impacts, or other quantitative data are disclosed in the provided filing summary. Sector not specified.
09-01-2026
Prelude Therapeutics Inc filed a Form 8-K on January 09, 2026 (AccNo: 0001193125-26-008280, Size: 14 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No core event details, transaction values, financial metrics, or other specifics are disclosed in the provided filing summary. Sector is not specified.
09-01-2026
Hillenbrand, Inc. filed an 8-K on January 9, 2026, under Item 7.01 for Regulation FD Disclosure. Accession number: 0001104659-26-002324; file size: 205 KB. No specific details on the disclosure content, events, transactions, or financial metrics are provided in the filing summary.
09-01-2026
NewAmsterdam Pharma Co N.V. filed an 8-K on January 9, 2026 (AccNo: 0001193125-26-008300, Size: 269 KB), reporting under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a financial results disclosure for a company in an unspecified sector. No specific financial metrics, transaction values, or other quantitative details are provided in the filing summary.
09-01-2026
Intellia Therapeutics, Inc. filed a Form 8-K on January 9, 2026 (AccNo: 0001193125-26-008307, Size: 5 MB), reporting under Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). No specific details on events, transactions, financial impacts, or quantitative data are explicitly stated in the provided filing summary. This is a multi-item voluntary or mandatory disclosure depending on the underlying events, but core event details are NOT_DISCLOSED.
09-01-2026
Savara Inc filed a Form 8-K on January 09, 2026 (AccNo: 0001193125-26-008301, size: 6 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No core event, transaction details, financial metrics, or other specifics are disclosed in the provided filing summary. This is a general filing from the US SEC with sector not specified.
09-01-2026
Compass, Inc. filed an 8-K on 2026-01-09 (AccNo: 0001563190-26-000019, Size: 1 MB) disclosing a merger/acquisition event via Items 1.01 (Entry into Material Definitive Agreement), 2.01 (Completion of Acquisition or Disposition of Assets), 2.03 (Creation of Direct Financial Obligation), 3.02 (Unregistered Sales of Equity Securities), 5.02 (Changes in Directors/Officers), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). No specific parties, deal structure, valuation, consideration type, synergies, regulatory details, shareholder impacts, or quantitative financial metrics are disclosed in the provided filing summary. Sector not specified.
09-01-2026
Koppers Holdings Inc. filed a Form 8-K on January 9, 2026 (AccNo: 0001315257-26-000004, Size: 342 KB) disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements). The filing also includes Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). No specific details on the officer, position, reason, or quantitative data provided in the summary; sector not specified.
09-01-2026
Cartesian Therapeutics, Inc. filed a Form 8-K on January 09, 2026 (AccNo: 0001453687-26-000051, Size: 7 MB) reporting Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No details on the core event, transaction values, financial metrics, or other specifics are provided in the filing summary. All quantitative financial data is NOT_DISCLOSED.
09-01-2026
AXT INC filed a Form 8-K on January 09, 2026 (AccNo: 0001213900-26-002690, Size: 215 KB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing disclosing financial results from US market. No specific financial metrics, transaction details, or numerical data are provided in the filing summary.
09-01-2026
Aptevo Therapeutics Inc. filed a Form 8-K on January 9, 2026 (AccNo: 0001193125-26-008318, size: 700 KB), reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on the agreement, equity sales, events, or quantitative data provided in the summary. Sector not specified.
09-01-2026
Atossa Therapeutics, Inc. filed a Form 8-K on January 9, 2026 (AccNo: 0001193125-26-008314, Size: 8 MB), disclosing financial results under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing focused on financial results. No specific quantitative financial metrics, transaction values, or other numerical data are mentioned.
09-01-2026
Rigetti Computing, Inc. filed a General Filing (likely Form 8-K) on January 09, 2026 (AccNo: 0001104659-26-002328, Size: 251 KB), reporting under Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). No specific details on events, transactions, financials, or named entities are disclosed in the provided filing summary. Sector is not specified.
09-01-2026
Ondas Holdings Inc. filed a Form 8-K on January 09, 2026 (AccNo: 0001213900-26-002694, Size: 200 KB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on the content of the disclosure, events, transactions, financial statements, or exhibits are provided in the filing summary. Sector is not specified.
09-01-2026
Evolus, Inc. filed a Form 8-K on January 9, 2026 (AccNo: 0001570562-26-000003, Size: 201 KB), reporting under Item 2.02 for Results of Operations and Financial Condition and Item 9.01 for Financial Statements and Exhibits. This constitutes a multi-item voluntary disclosure of financial results. No specific revenue, earnings, transaction values, or other quantitative financial metrics are disclosed in the provided filing summary.
09-01-2026
Anywhere Real Estate Inc. filed an 8-K on 2026-01-09 (AccNo: 0001193125-26-008327, Size: 290 KB) announcing completion of an acquisition or disposition of assets (Item 2.01), notice of delisting or failure to satisfy listing standards (Item 3.01), material modifications to rights of security holders (Item 3.03), changes in control of the registrant (Item 5.01), changes in directors/officers (Item 5.02), and amendments to articles of incorporation or bylaws (Item 5.03). Item 9.01 includes financial statements and exhibits. No specific details on parties, deal structure, valuation, or financial metrics are disclosed.
09-01-2026
GRI Bio, Inc. filed a Form 8-K on January 9, 2026 (AccNo: 0001824293-26-000006, size: 206 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the other event, transaction, financial statements, or exhibits are disclosed in the provided filing summary. Sector is not specified.
09-01-2026
CG Oncology, Inc. filed a Form 8-K on January 9, 2026 (AccNo: 0001193125-26-008329, Size: 15 MB) as a General Filing from us_sec, reporting under Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on events, transactions, financials, or quantitative data provided in the summary. Sector is not specified.
Get daily alerts with 4 investment signals, 4 risk alerts, 4 opportunities and full AI analysis of all 49 filings
🇺🇸 More from United States
View all →March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC
March 24, 2026
US Corporate Distress Financial Stress SEC Filings — March 24, 2026
US Corporate Distress Financial Stress SEC Filings